Abstract
The direct inhibitors of thrombin (dabigatran) or factor Xa (rivaroxaban, apixaban) are currently used in patients with venous thrombosis of the lower or upper limbs or with pulmonary embolism. However, the use of these direct oral anticoagulants (DOACs) in subjects with abdominal or cerebral venous thrombosis is more contentious due to the paucity of available data. In a few case reports and small series of patients hitherto published, the DOACs showed good efficacy and safety, supporting an extension of their use to these rare conditions. Thus, prospective cohort studies and randomized controlled trials have been set up. In this article, we review the published clinical experience with DOACs in rare venous thrombosis, and provide updated information on ongoing clinical trials.
This is a preview of subscription content, log in via an institution to check access.
References
van Es N, Coppens M, Schulman S, Middeldorp S, Büller HR (2014) Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 124:1968–1975
Pannach S, Babatz J, Beyer-Westendorf J (2013) Successful treatment of acute portal vein thrombosis with rivaroxaban. Thromb Haemost 110:626–627
Martinez M, Tandra A, Vuppalanchi R (2014) Treatment of Acute portal vein thrombosis by nontraditional anticoagulation. Hepatology 60:425–426
Intagliata NM, Maitland H, Northup PG, Caldwell SH (2015) Treating thrombosis in cirrhosis patients with new oral agents: ready or not? Hepatology 61:738–739
Simonetto DA, Wysokinski WE, Kamath PS (2015) Use of nontraditional anticoagulants in portal vein thrombosis: a note of caution. Hepatology 61:2119
Russmann S, Niedrig DF, Budmiger M et al (2014) Rivaroxaban postmarketing risk of liver injury. J Hepatol 61:293–300
Pollack CV Jr, Reilly PA, Eikelboom J et al (2015) Idarucizumab for dabigatran reversal. N Engl J Med 373:511–520
Siegal DM, Curnutte JT, Connolly SJ et al (2015) Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 373:2413–2424
Potze W, Adelmeijer J, Lisman T (2015) Decreased in vitro anticoagulant potency of Rivaroxaban and Apixaban in plasma from patients with cirrhosis. Hepatology 61:1435–1436
Jones C, Levy Y, Tong AW (2014) Elevated serum erythropoietin in a patient with polycythaemia vera presenting with Budd-Chiari syndrome. BMJ Case Rep. doi:10.1136/bcr-2014-205663
Pedersen MR, Molloy P, Wood D, Seetharam A (2016) Direct intrahepatic portocaval shunt for treatment of portal thrombosis and Budd-Chiari syndrome. Ann Hepatol 15:127–130
Reshetnyak TM, Seredavkina NV, Satybaldyeva MA, Nasonov EL, Reshetnyak VI (2015) Liver transplantation in a patient with primary antiphospholipid syndrome and Budd-Chiari syndrome. World J Hepatol 7:2229–2236
Geisbüsch C, Richter D, Herweh C, Ringleb PA, Nagel S (2014) Novel factor Xa inhibitor for the treatment of cerebral venous and sinus thrombosis. First experience in 7 patients. Stroke 45:2469–2471
Mendonça MD, Barbosa R, Cruz-e-Silva V, Calado S, Viana-Baptista M (2015) Oral direct thrombin inhibitor as an alternative in the management of cerebral venous thrombosis: a series of 15 patients. Int J Stroke 10:1115–1118
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Statement of human and animal rights
This article does not contain any studies with human participants or animals performed by any of the authors.
Informed consent
Our study did not require informed consent as there were no participants involved.
Rights and permissions
About this article
Cite this article
Finazzi, G., Ageno, W. Direct oral anticoagulants in rare venous thrombosis. Intern Emerg Med 11, 167–170 (2016). https://doi.org/10.1007/s11739-016-1398-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11739-016-1398-6